Clinical trials: Respiratory Tract Infection
Respiratory Syncytial Virus Infections
A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT
Objectives Primary Objectives: Pilot Study: A preliminary assessment of the exposure and safety of oral A-60444 in post-stem cell transplant patients with RSV infection.
- Trial name
- NCT00232635
- Testing
- A-60444
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- Arrow Therapeutics
Rhinoconjunctivitis, Rhinitis
Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)
The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma.
- Conditions
- Rhinoconjunctivitis, Rhinitis, Conjunctivitis, Allergy
- Trial name
- NCT00550550
- Testing
- SCH 697243, Loratadine Syrup 1 mg/mL Rescue Treatment, Loratadine 10 mg Rescue Treatment
- Volunteers
- 345 people
- Sponsor
- ALK-Abelló A/S
Influenza
Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly
Since influenza vaccines are normally administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of adjuvanted influenza vaccine need to be re-evaluated after…
- Trial name
- NCT00386113
- Testing
- Fluarix and adjuvanted influenza vaccine
- Where
- Belgium
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Covid19, SARS-CoV-2 Infection
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
A Trial of GC4419 in Patients with Critical Illness due to COVID-19
- Trial name
- NCT04555096
- Testing
- GC4419
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Galera Therapeutics, Inc.
COVID-19
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
The purpose of this study is to learn about the side effects (safety) of the study medicine PF-07321332 (nirmatrelvir)/ritonavir for the treatment of mild to moderate COVID-19 infection in adults with severe renal impairment.
- Trial name
- NCT05487040
- Testing
- PF-07321332 (nirmatrelvir)/ritonavir
- Where
- 52 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Pneumonia, Community-Acquired, Bacterial Pneumonia
Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)
The goal of this clinical trial is to evaluate the efficacy and safety of faropenem in comparison to co-amoxiclav and clarithromycin in Bangladeshi adults diagnosed with community-acquired bacterial pneumonia (CABP).
- Trial name
- NCT06804096
- Testing
- Faropenem, Co-amoxiclav, Clarithromycin 500 mg
- Where
- 2 sites in Bangladesh
- Volunteers
- 129 people
- Sponsor
- Dr. Md. Alimur Reza
SARS CoV 2 Infection
Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence
This is a Phase II study with single-blinded safety phase followed by double-blinded randomization, placebo-controlled, of administration of a single dose by two different administration routes (intramuscular route or intranasal…
- Trial name
- NCT05205746
- Testing
- Recombinant NDV Vectored Vaccine for SARS-CoV-2
- Where
- 4 sites in Mexico
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Laboratorio Avi-Mex, S.A. de C.V.
SARS-CoV2 Infection
Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients
In COVID-19 infection caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a dysregulation of the immune system response that causes cytokine storm syndrome.
- Trial name
- EXOMSC-COV19 (NCT05216562)
- Testing
- Exosome-MSC Intravenous injection, COVID-19 Standard Treatment
- Where
- 3 sites in Indonesia
- Volunteers
- 60 people
- Sponsor
- Dermama Bioteknologi Laboratorium
Influenza
Bifidobacterium Lactis HN019 Supplementation for Prevention of Influenza Infection in Healthy Adults
To determine if prophylactic supplementation with B. lactis HN019 reduces the risk of developing physician- and laboratory-confirmed influenza infection at any time during the 12-week supplementation period.
- Trial name
- NCT01258842
- Testing
- Bifidobacterium lactis HN019
- Where
- 2 sites in United States
- Volunteers
- 426 people, healthy volunteers welcome
- Sponsor
- Fonterra Research Centre
Influenza
Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza
This is a randomized clinical trial designed to evaluate oral nitazoxanide compared to a placebo in the treatment of acute uncomplicated influenza in adults.
- Trial name
- NCT01056380
- Testing
- Nitazoxanide
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Romark Laboratories L.C.
Rhinitis, Conjunctivitis
Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients
The aim of this study is to test the pharmacodynamic equivalence with respect to IgE-blocking factor and to compare the tolerability of two different updosing schedules with ALK-Flex SQ
- Conditions
- Rhinitis, Conjunctivitis, Asthma
- Trial name
- NCT00857779
- Testing
- subcutaneous immunotherapy
- Where
- Germany
- Volunteers
- 473 people
- Sponsor
- ALK-Abelló A/S
COVID-19, Pneumonia
Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)
This study adopts a randomized, double-blind, placebo parallel control design, and is expected to include 168 eligible patients with severe novel coronavirus pneumonia.
- Trial name
- COVID-19 (NCT05702788)
- Testing
- Jaktinib hydrochloride tablets
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis
The primary objective of this study is to investigate the effect of 4-week treatment with 7.5 mg b.i.d, 15 mg q.d and 15 mg b.i.d.
- Trial name
- NCT00726479
- Testing
- BIBW 2948 BS
- Where
- 24 sites in United States, France and 1 more
- Sponsor
- Boehringer Ingelheim
Common Cold
Nasal Swab Study to Explore the Nasal Microbia
The objective of this study is to evaluate the microbial consortia and the host inflammatory factors present in the nasal passages of patients during upper respiratory symptomology and when healthy using culture and molecular…
- Trial name
- NCT02535442
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Kimberly-Clark Corporation
Infections, Streptococcal, Streptococcus Pneumoniae
Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease
The aim of this study is to assess the effectiveness of GSK Biologicals' pneumococcal conjugate vaccine (GSK1024850A), administered according to different vaccination schedules, against invasive disease caused by S.
- Trial name
- FinIP (NCT00861380)
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine), GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)
- Where
- Finland
- Volunteers
- 41,188 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19
Objective of the study: to investigate the effect of meglumine succinate solution on the dynamics of metabolic blood parameters and respiratory function of the lungs in intensive care patients with new coronavirus infection.
- Trial name
- CARECOVID (NCT05172180)
- Testing
- Reamberin, Ringer's solution
- Where
- Russia
- Volunteers
- 105 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Acute Bronchitis
Evaluate the Efficacy and Safety of Andrographolide Sulfonate in Patients With Acute Bronchitis
A multicenter, randomized, double-blind, placebo-controlled, phase 4 clinical trial to evaluate the efficacy and safety of andrographolide sulfonate in patients with acute bronchitis
- Trial name
- NCT03132623
- Testing
- andrographolide sulfonate, andrographolide sulfonate simulation
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Coronavirus Disease 2019 (COVID-19)
Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
This study evaluates the efficacy and safety of efprezimod alfa in hospitalized adult participants who are diagnosed with coronavirus disease 2019 (COVID-19) and receiving oxygen support.
- Trial name
- SAC-COVID (NCT04317040)
- Testing
- Efprezimod alfa
- Where
- 10 sites in United States
- Volunteers
- 234 people
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Rhinitis
Efficacy and Safety Study of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults
To demonstrate the superiority of the clinical efficacy of 12 weeks' treatment with Nasacort versus placebo in adult patients presenting with Chronic Non Allergic and Non Infectious Rhinitis
- Trial name
- RhiCNANI (NCT00344942)
- Testing
- triamcinolone acetonide
- Where
- France
- Volunteers
- 77 people
- Sponsor
- Sanofi
COVID-19
A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines.
This is a study to evaluate the ability of UB-612 vaccine to boost immunity of subjects who previously received two doses of AstraZeneca COVID-19 vaccine (ChAdOx1-S) with an 8-16 week interval between first and second doses.
- Trial name
- NCT05167253
- Testing
- UB-612
- Volunteers
- healthy volunteers welcome
- Sponsor
- United Biomedical Inc., Asia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.